BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34329798)

  • 1. Variants in CASP10, a diagnostic challenge: Single center experience and review of the literature.
    Matas Pérez E; Valdivieso Shephard JL; Bravo García-Morato M; Robles Marhuenda Á; Martinez-Ojinaga Nodal E; Prieto Bozano G; González Casado I; Salamanca Fresno L; Méndez Echevarria A; Del Rosal Rabes T; Allende Martínez L; López-Granados E; Rodríguez Pena R
    Clin Immunol; 2021 Sep; 230():108812. PubMed ID: 34329798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAS-mediated apoptosis impairment in patients with ALPS/ALPS-like phenotype carrying variants on CASP10 gene.
    Miano M; Cappelli E; Pezzulla A; Venè R; Grossi A; Terranova P; Palmisani E; Maggiore R; Guardo D; Lanza T; Calvillo M; Micalizzi C; Pierri F; Vernarecci C; Beccaria A; Corsolini F; Lanciotti M; Russo G; Ceccherini I; Dufour C; Fioredda F
    Br J Haematol; 2019 Nov; 187(4):502-508. PubMed ID: 31309545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome.
    Consonni F; Moreno S; Vinuales Colell B; Stolzenberg MC; Fernandes A; Parisot M; Masson C; Neveux N; Rosain J; Bamberger S; Vigue MG; Malphettes M; Quartier P; Picard C; Rieux-Laucat F; Magerus A
    Cell Death Dis; 2024 May; 15(5):315. PubMed ID: 38704374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.
    Martínez-Feito A; Melero J; Mora-Díaz S; Rodríguez-Vigil C; Elduayen R; González-Granado LI; Pérez-Méndez D; Sánchez-Zapardiel E; Ruiz-García R; Menchén M; Díaz-Madroñero J; Paz-Artal E; Del Orbe-Barreto R; Riñón M; Allende LM
    Immunobiology; 2016 Jan; 221(1):40-7. PubMed ID: 26323380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exonic deletion of CASP10 in a patient presenting with systemic juvenile idiopathic arthritis, but not with autoimmune lymphoproliferative syndrome type IIa.
    Tadaki H; Saitsu H; Kanegane H; Miyake N; Imagawa T; Kikuchi M; Hara R; Kaneko U; Kishi T; Miyamae T; Nishimura A; Doi H; Tsurusaki Y; Sakai H; Yokota S; Matsumoto N
    Int J Immunogenet; 2011 Aug; 38(4):287-93. PubMed ID: 21382177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical presentation of autoimmune lymphoproliferative syndrome due to CASP10 mutation.
    Tripodi SI; Mazza C; Moratto D; Ramenghi U; Caorsi R; Gattorno M; Badolato R
    Immunol Lett; 2016 Sep; 177():22-4. PubMed ID: 27378136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next Generation Sequencing for Detecting Somatic
    López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
    Front Immunol; 2021; 12():656356. PubMed ID: 33995372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation.
    Paskiewicz A; Niu J; Chang C
    Autoimmun Rev; 2023 Nov; 22(11):103442. PubMed ID: 37683818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the Spectrum of Immune Dysregulation Manifestations in Autoimmune Lymphoproliferative Syndrome and Autoimmune Lymphoproliferative Syndrome-like Disorders.
    Failing C; Blase JR; Walkovich K
    Rheum Dis Clin North Am; 2023 Nov; 49(4):841-860. PubMed ID: 37821199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key diagnostic markers for autoimmune lymphoproliferative syndrome with molecular genetic diagnosis.
    Molnár E; Radwan N; Kovács G; Andrikovics H; Henriquez F; Zarafov A; Hayman M; Linzner D; Thrasher AJ; Buckland M; Burns SO; Gilmour KC
    Blood; 2020 Oct; 136(17):1933-1945. PubMed ID: 32599613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in autoimmune lymphoproliferative syndromes.
    Madkaikar M; Mhatre S; Gupta M; Ghosh K
    Eur J Haematol; 2011 Jul; 87(1):1-9. PubMed ID: 21447005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
    Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
    Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and evolutionary dynamics of somatic FAS variants in autoimmune lymphoproliferative syndrome: Diagnostic implications.
    Batlle-Masó L; Garcia-Prat M; Parra-Martínez A; Franco-Jarava C; Aguiló-Cucurull A; Velasco P; Antolín M; Rivière JG; Martín-Nalda A; Soler-Palacín P; Martínez-Gallo M; Colobran R
    Front Immunol; 2022; 13():1014984. PubMed ID: 36466883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome.
    Zhu S; Hsu AP; Vacek MM; Zheng L; Schäffer AA; Dale JK; Davis J; Fischer RE; Straus SE; Boruchov D; Saulsbury FT; Lenardo MJ; Puck JM
    Hum Genet; 2006 Apr; 119(3):284-94. PubMed ID: 16446975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune Lymphoproliferative Syndrome (ALPS) Disease and ALPS Phenotype: Are They Two Distinct Entities?
    Palmisani E; Miano M; Grossi A; Lanciotti M; Lupia M; Terranova P; Ceccherini I; Montanari E; Calvillo M; Pierri F; Micalizzi C; Maggiore R; Guardo D; Zanardi S; Facchini E; Maggio A; Mastrodicasa E; Corti P; Russo G; Pillon M; Farruggia P; Cesaro S; Barone A; Tosetti F; Ramenghi U; Crescenzio N; Bleesing J; Dufour C; Fioredda F
    Hemasphere; 2023 Mar; 7(3):e845. PubMed ID: 36844186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of rare copy number variants in FAS toward pathogenesis of autoimmune lymphoproliferative syndrome.
    Jevtich K; Price S; Similuk M; Kulm E; Yan J; Setzer M; Jamal L; Franco LM; Ghosh R; Walkiewicz M; Rao VK
    Blood Adv; 2022 Jul; 6(13):3974-3978. PubMed ID: 35476126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I treat autoimmune lymphoproliferative syndrome.
    Rao VK; Oliveira JB
    Blood; 2011 Nov; 118(22):5741-51. PubMed ID: 21885601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).
    Teachey DT; Seif AE; Grupp SA
    Br J Haematol; 2010 Jan; 148(2):205-16. PubMed ID: 19930184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS).
    Li P; Huang P; Yang Y; Hao M; Peng H; Li F
    Clin Rev Allergy Immunol; 2016 Feb; 50(1):55-63. PubMed ID: 25663566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
    Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
    Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.